NPH 29

Drug Profile

NPH 29

Alternative Names: NPH29

Latest Information Update: 07 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator nPharmakon LLC
  • Class Amines; Anti-inflammatories; Benzyl compounds; Pyrazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Hyperpigmentation

Most Recent Events

  • 01 Jul 2015 NPH 29 is available for licensing as of 07 Jul 2015.
  • 01 Jul 2015 Efficacy and adverse events data from a clinical study in Hyperpigmentation released by nPharmakon
  • 01 Jun 2015 nPharmakon receives notice of allowance for NPH 29 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top